Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer

Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies

(2017) J. J. Stephenson et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I-II open-label trial of ispinesib on an alternate dosing schedule in chemotherapy-naive patients with locally advanced or metastatic breast cancer (MBC)

(2017) M. Philco et al.   JOURNAL OF CLINICAL ONCOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

(2011) J. R. Infante et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Prognostic Factors in Second-Line Treatment of Urothelial Cancers With Gemcitabine and Paclitaxel (German Association of Urological Oncology Trial AB20/99)

(2011) Günter Niegisch et al.   EUROPEAN UROLOGY

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia

(2011) H. M. Kantarjian et al.   INVESTIGATIONAL NEW DRUGS

Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]

(2010) P. Albers et al.   ANNALS OF ONCOLOGY

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

(2009) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanism of Inhibition of Human KSP byIspinesib

(2008) Latesh Lad et al.   BIOCHEMISTRY

Targeting the Kinesin Spindle Protein: Basic Principles and Clinical Implications

(2008) V. Sarli et al.   CLINICAL CANCER RESEARCH

A University of Chicago Consortium Phase II Trial of SB-715992 in Advanced Renal Cell Cancer

(2008) Richard T. Lee et al.   Clinical Genitourinary Cancer

Mechanisms Underlying Chemotherapy-Induced Neurotoxicity and the Potential for Neuroprotective Strategies

(2008) S. Park et al.   CURRENT MEDICINAL CHEMISTRY

A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)

(2008) Jennifer J. Knox et al.   INVESTIGATIONAL NEW DRUGS

Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer

(2008) Christopher D. Cox et al.   JOURNAL OF MEDICINAL CHEMISTRY